Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Chipscreen Poised to be One of the First IPOs on Shanghai's STAR Exchange

publication date: Jul 18, 2019

Shenzhen Chipscreen Biosciences is expected to be one of the first IPOs on Shanghai's new STAR Board for young technology companies. STAR IPOs are expected to begin next week. Chipscreen specializes in discovering and developing novel small molecule drugs for needs in oncology, metabolic disease and autoimmune disease. Unlike many STAR IPO companies, Chipscreen is profitable. In 2015, its cancer drug, Chidamide, was launched in China to treat NHL T-Cell lymphoma. It is currently being tested for US approval. The company currently has 14 research projects underway. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here